Correspondence
Long-term safety of targeted agents used to treat metastatic renal cell carcinoma: the issue is not the rate of adverse events over time, but the expertise needed to manage them
Abstract
Targeted agents have revolutionized the treatment of advanced renal cell carcinoma (RCC), greatly improving the survival of patients affected with once orphan disease.
